A total of 124 NSCLC, including 121 adenocarcinoma, 2 NSCLC-NOS and 1 SCC, patients who received EGFR TKIs as the front-line treatment for their advanced NSCLC with EGFR mutations were identified for the analyses (Figure 1), with a mean age: 68.2±13.0 years, and median follow-up time: 9.8 months (inter-quartile rage  = 4.8–16.1 months). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.